CXCL12 and myeloid sarcoma: Finally, a cross-disease study was performed to monitor CXCL12 levels in sALS, multiple sclerosis (MS), Alzheimer’s disease (AD), frontotemporal dementia behavioral variant (FTD), and type III spinal muscular atrophy (SMA).